长效卡博特韦治疗HIV的病毒学失败与新发整合酶链转移抑制剂耐药:一项Meta分析
该Meta分析汇总33项研究(N=9224)的病毒学失败数据和19项研究(N=5662)的耐药数据,评估长效卡博特韦联合利匹韦林(CAB/RPV)治疗HIV的病毒学失败与新发整合酶链转移抑制剂(INSTI)耐药。病毒学失败率在诱导-维持研究为1%(95%CI 1%-3%),转换时已抑制研究为1%(1%-2%),转换时有病毒血症研究为5%(3%-10%);失败时成功基因型检测者中INSTI耐药率分别为71%(25%-95%)、61%(44%-75%)和41%(20%-65%)。作者结论认为尽管病毒学失败率低,但INSTI耐药在约40%-70%的病毒学失败者中出现,显著高于口服INSTI方案。
要点
- CAB/RPV病毒学失败率:诱导-维持1%(95%CI 1%-3%),转换已抑制1%(1%-2%),转换有病毒血症5%(3%-10%)。
- 失败时成功基因型检测者中INSTI耐药率分别为71%(25%-95%)、61%(44%-75%)和41%(20%-65%)。
- 多替拉韦交叉耐药常见,占新发耐药者的64%。
核心结论
- 尽管CAB/RPV的病毒学失败率低,但约40%-70%的病毒学失败者出现INSTI耐药,显著高于口服INSTI方案。
- 在CAB/RPV使用扩大的人群中,可能需要进行个体水平和更广泛的耐药监测。
研究设计与样本
- 系统检索临床试验注册库、PubMed、EMBASE和会议摘要数据库,纳入报告CAB/RPV用于HIV治疗的文献。
- 提取48周(范围24-52周)病毒学失败和新发INSTI耐药数据,采用单比例Meta分析汇总3类人群结局。
- 33项研究(N=9224)报告病毒学失败率,19项研究(N=5662)报告耐药数据;使用Cochrane RoB 2.0和ROBINS-1工具评估偏倚风险。
主要发现
- 病毒学失败率:诱导-维持研究1%(95%CI 1%-3%),转换时已抑制研究1%(95%CI 1%-2%),转换时有病毒血症研究5%(95%CI 3%-10%)。
- 失败时成功基因型检测者中INSTI耐药率:诱导-维持研究71%(95%CI 25%-95%),转换时已抑制研究61%(95%CI 44%-75%),转换时有病毒血症研究41%(95%CI 20%-65%)。
- 多替拉韦交叉耐药常见,占新发耐药者的64%。
临床怎么用
- 作者认为,在CAB/RPV使用扩大的人群中,可能需要进行个体水平和更广泛的耐药监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-acting injectable regimen of cabotegravir plus rilpivirine (CAB/RPV) emerged as an alternative to oral standard-of-care integrase strand transfer inhibitor (INSTI)-based regimens for individuals with adherence challenges or preference for reduced dosing schedules. Although oral INSTI regimens have a high barrier to emergent resistance, less is known about the potency and durability of CAB/RPV. METHODS: We reviewed clinical trial registries, PubMed, EMBASE, and conference abstract databases to identify reports of CAB/RPV for HIV therapy. We abstracted data on virologic failure (VF) and treatment-emergent INSTI resistance at 48 weeks (range: 24-52). We used single-proportion meta-analysis to summarize outcomes in 3 populations: antiretroviral therapy (ART)-naive individuals initiating CAB/RPV following suppression on oral ART, ART-experienced individuals switched to CAB/RPV with virologic suppression, and ART-experienced individuals switched to CAB/RPV with detectable viremia. Cochrane's RoB 2.0 and ROBINS-1 tools assessed risk of bias. RESULTS: Thirty-three studies (N = 9224) reported VF prevalence. Nineteen studies (N = 5662) reported resistance data. VF prevalence was 1% (95% CI: 1%-3%) in induction-maintenance studies, 1% (1%-2%) in switch-suppressed studies, and 5% (3%-10%) in switch-viremic studies. INSTI resistance prevalence among successfully genotyped participants at failure was 71% (25%-95%), 61% (44%-75%), and 41% (20%-65%) respectively. Dolutegravir cross-resistance was common (64% of those with emergent resistance). CONCLUSIONS: Although VF rates with CAB/RPV were low, INSTI resistance emerged in approximately 40%-70% of individuals experiencing VF. These rates are significantly higher than those for oral INSTI-based regimens. Both individual-level and broader resistance surveillance may be warranted in populations with expanding CAB/RPV use. Clinical Trials Registration. PROSPERO registration CRD42024543919.
引用
- Perez Navarro A, Nutt CT, Siedner MJ, et al. Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis. Clin Infect Dis. 2025. PMID: 39724249. doi:10.1093/cid/ciae631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。